CD4 and renal cell carcinoma: Furthermore, we observed that T cells within the RCC TME, including both CD4+ and CD8+ subsets, expressed elevated levels of CD70 compared to other immune cell types, rendering them potential targets for CD70-directed CAR therapies (Figures 1N and 1O).